David Matthew Altshuler (born August 27, 1964)[3] is a clinical endocrinologist and human geneticist.

He is Executive Vice President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals.

He was also a faculty member in the Department of Molecular Biology, Center for Human Genetic Research, and the Diabetes Unit, all at Massachusetts General Hospital.

[6][7] Altshuler attended Commonwealth School in Boston, received his Bachelor of Science from Massachusetts Institute of Technology,[8] his Ph.D from Harvard University, and his M.D.

[14] He has co-led the SNP Consortium, International HapMap Project,[15][16] and 1000 Genomes Project[17][18][19] His research focused on the genetic basis of Type 2 Diabetes, and his laboratory contributed to mapping dozens of gene variants that are associated with risk of Type 2 Diabetes, lipid levels, myocardial infarction, rheumatoid arthritis, lupus, prostate cancer, and other disorders.